FDMT director granted options on 50,000 shares

4D Molecular Therapeutics director Shawn Tomasello received a new stock option grant as part of non-employee director compensation.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

4D Molecular Therapeutics director Shawn Tomasello received a new stock option grant as part of non-employee director compensation. The award covers options to buy 50,000 shares of common stock at an exercise price of $9.42 per share, expiring on June 16, 2036.

One-third of the option vests on June 17, 2027, with the remaining shares vesting in equal monthly installments until fully vested on June 17, 2029, provided she continues serving the company. The option will vest in full if a Change in Control occurs under the company’s 2020 Incentive Award Plan.

Insights

Routine director option grant with time-based and change-in-control vesting.

The filing shows **Shawn Tomasello**, a director of **4D Molecular Therapeutics**, receiving a grant of stock options covering 50,000 shares of common stock at an exercise price of $9.42 per share. This is a compensation-related award, not an open-market trade.

The options vest over time: one-third on June 17, 2027, then in equal monthly installments until fully vested on June 17, 2029, contingent on continued board service. The options expire on June 16, 2036, giving a long exercise window.

The footnotes also state that the options vest in full upon a Change in Control as defined in the 2020 Incentive Award Plan. This single-trigger acceleration is common in director packages and primarily affects outcomes if the company is acquired, without signaling any view on current valuation.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Tomasello Shawn

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 50,000 contracts (Direct)

Footnotes (2)

F1. Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2. The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Key Figures

Option grant size: 50,000 options Exercise price: $9.42 per share Post-grant derivative holdings: 50,000 options +3 more

6 metrics

Option grant size 50,000 options Stock Option (Right to Buy) covering common stock

Exercise price $9.42 per share Conversion or exercise price for granted stock options

Post-grant derivative holdings 50,000 options Total derivative securities following the transaction

Option expiration June 16, 2036 Expiration date of the stock option award

Initial vesting date June 17, 2027 Date when one-third of the options vest

Full vesting date June 17, 2029 Date when options become fully vested absent acceleration

Key Terms

Stock Option (Right to Buy), non-employee director compensation program, Change in Control, 2020 Incentive Award Plan, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

non-employee director compensation program financial

"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."

Change in Control financial

"Additionally, the stock options will vest in full upon the consummation of a Change in Control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

2020 Incentive Award Plan financial

"Change in Control (as defined in the 2020 Incentive Award Plan)."

vests and becomes exercisable financial

"The stock option vests and becomes exercisable with respect to 1/3 of the total shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FDMT director Shawn Tomasello receive in this Form 4 filing?

Shawn Tomasello received a stock option grant to purchase 50,000 shares of 4D Molecular Therapeutics common stock. The options were granted at an exercise price of $9.42 per share as part of the company’s non-employee director compensation program, rather than through an open-market transaction.

What is the exercise price and term of Shawn Tomasello’s FDMT stock options?

The stock options have an exercise price of $9.42 per share and expire on June 16, 2036. This long term gives the director significant time to decide whether to exercise based on 4D Molecular Therapeutics’ performance and share price over the coming years.

How do the 50,000 FDMT stock options granted to Shawn Tomasello vest?

One-third of the 50,000 options vest on June 17, 2027, with the remaining two-thirds vesting in equal monthly installments until June 17, 2029. Vesting depends on Shawn Tomasello continuing to provide service to 4D Molecular Therapeutics through each vesting date.

Does a Change in Control affect Shawn Tomasello’s FDMT stock option vesting?

Yes. The stock options will vest in full upon the consummation of a Change in Control, as defined in 4D Molecular Therapeutics’ 2020 Incentive Award Plan. This means all unvested options accelerate if a qualifying transaction, such as an acquisition, is completed.

Is Shawn Tomasello’s FDMT Form 4 transaction a market purchase or sale of shares?

No. The Form 4 reports a compensation-related grant of stock options, not a market purchase or sale of common shares. The options were automatically granted under the non-employee director compensation program and do not involve immediate cash outlay or trading in FDMT stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2026 - 05:43 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tomasello Shawn

(Last)

(First)

(Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE

CALIFORNIA

94608

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$9.42	06/17/2026		A⁽¹⁾		50,000		⁽²⁾	06/16/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

2. The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

	/s/ Scott Bizily as Attorney-in-Fact for Shawn Cline Tomasello	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FDMT director granted options on 50,000 shares

Rhea-AI Filing Summary